=>
Uploading 050.str

L1 STRUCTURE UPLOADED

=> s l1 sss ful
FULL SEARCH INITIATED 17:16:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2251 TO ITERATE

100.0% PROCESSED 2251 ITERATIONS 47 ANSWERS
SEARCH TIME: 00.00.01

L2 47 SEA SSS FUL L1

=> d scan

L2 47 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylphenyl]amino]-3-oxo- (9CI)
MF C19 H19 Cl2 N O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):n

```
=> d his

     (FILE 'HOME' ENTERED AT 17:15:41 ON 11 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 17:15:59 ON 11 DEC 2003
L1              STRUCTURE UPLOADED
L2           47 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 17:17:05 ON 11 DEC 2003

=> s l2
L3            6 L2

=> d bib, hit 1-
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y


L3   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:376560  CAPLUS
DN   138:385172
TI   Process for the preparation of aniline-derived thyroid receptor ligands
     with improved safety and economy
IN   Chidambaram, Ramakrishnan; Kant, Joydeep; Weaver, Raymond E., Jr.; Yu,
     Jurong; Ghosh, Arun
PA   Bristol-Myers Squibb Company, USA
SO   PCT Int. Appl., 70 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.   DATE
     ---------------    ----  --------       ---------------   --------
PI   WO 2003039456      A2    20030515       WO 2002-US34592   20021028
     WO 2003039456      A3    20031002
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     US 2003157671      A1    20030821       US 2002-273268    20021017
PRAI US 2001-336318P    P     20011102
OS   MARPAT 138:385172
IT   355129-15-6P, N-[3,5-Dibromo-4-(4-hydroxy-3-
     isopropylphenoxy)phenyl]malonamic acid 355129-16-7P,
     N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenyl]malonamic acid
     355129-17-8P, N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)-2-
     methylphenyl]malonamic acid 355129-18-9P, N-[3,5-Dibromo-4-(4-
     hydroxy-3-isopropylphenoxy)phenyl]succinamic acid 525584-74-1P,
     N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)-2-methylphenyl]malonamic
     acid 525584-75-2P, N-[3,5-Dichloro-4-(4-hydroxy-3-
     isopropylphenoxy)phenyl]succinamic acid
     RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
     (Preparation)
        (process for prepn. of aniline-derived thyroid receptor ligands with
        improved safety and economy)
```

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:905927 CAPLUS
DN 138:305
TI Preventive or recurrence-suppressive agents for liver cancer
IN Ohnota, Hideki; Hayashi, Morimichi; Kuroda, Junji; Komatsu, Yoshimitsu; Nishimura, Toshihiro
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094319	A1	20021128	WO 2002-JP4601	20020513

PI
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2001-149775 A 20010518
OS MARPAT 138:305
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT **355129-15-6P** **355129-23-6P** 364331-19-1P 364331-20-4P
364331-24-8P 364332-53-6P 364332-59-2P 364332-60-5P 373641-10-2P
373641-11-3P 373641-12-4P 373641-13-5P 373641-14-6P 373641-15-7P
373641-16-8P 373641-17-9P 373641-18-0P 373641-19-1P 373641-20-4P
373641-22-6P 373641-24-8P 373641-25-9P 373641-27-1P 373641-29-3P
373641-31-7P 373641-34-0P 373641-36-2P 373641-38-4P
373641-40-8P 373641-42-0P 373641-44-2P 373641-46-4P
373641-48-6P 373641-49-7P 373641-50-0P 373641-51-1P 373641-53-3P
373641-54-4P 373641-56-6P 373641-57-7P 373641-58-8P 373641-59-9P
373641-60-2P 373641-61-3P 373641-62-4P 373641-63-5P
373641-64-6P 373641-65-7P 373641-66-8P 373641-67-9P 373641-68-0P
373641-69-1P 373641-70-4P 373641-71-5P 373641-72-6P 373641-73-7P
373641-74-8P 373641-75-9P 373641-76-0P 373641-77-1P 373641-78-2P
373641-79-3P 373641-80-6P 373641-81-7P 373641-82-8P 373641-83-9P
373641-84-0P 373641-85-1P 373641-86-2P 373641-87-3P 373641-88-4P
373641-89-5P 373641-90-8P 373641-91-9P 373641-92-0P 477274-10-5P
477274-11-6P 477274-12-7P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preventive or recurrence-suppressive agents for liver cancer contg. thyroid hormone receptor agonists)

IT 2423-71-4P, 2,6-Dimethyl-4-nitrophenol 3886-19-9P, 2,6-Dibenzyloxyacetophenone 4049-39-2P, 4-Benzyloxy-3-hydroxybenzaldehyde 20404-02-8P, 2,3,6-Trichloro-4-nitrophenol 23860-35-7P, Cyclohexylacetylchloride 29417-96-7P 40500-05-8P 53906-85-7P, 4-Iodo-3,5-dimethylnitrobenzene 85064-61-5P, 4-Tetrahydropyranylacetic acid 92892-06-3P 103260-44-2P 117832-15-2P 130312-00-4P 156740-97-5P, 4-(4-Methoxyphenoxy)-3,5-dimethylnitrobenzene 355377-72-9P, 5-(2,6-Dimethyl-4-nitrophenoxy)-2-methoxybenzaldehyde 373641-93-1P 373641-94-2P 373641-96-4P 373641-97-5P, 4-Benzyloxy-3-(4-fluorophenoxy)benzaldehyde 373641-98-6P 373641-99-7P

373642-00-3P 373642-01-4P 373642-02-5P 373642-03-6P, 4-Benzyloxy-3-isopropylbenzaldehyde 373642-05-8P 373642-07-0P 373642-09-2P 373642-10-5P 373642-12-7P 373642-14-9P 373642-16-1P 373642-18-3P 373642-20-7P, 1-Benzyloxy-4-(2,3,6-trichloro-4-nitrophenoxy)-5,6,7,8-tetrahydronaphthalene 373642-22-9P, 3-Chloro-6-[5-(2,6-dimethyl-4-nitrophenoxy)-2-methoxybenzyl]pyridazine 373642-24-1P, 1-[6-Benzyloxy-3-(2,6-dimethyl-4-nitrophenoxy)-2-hydroxyphenyl]ethanone 373642-26-3P, 1-[6-Benzyloxy-3-(2,6-dimethyl-4-nitrophenoxy)-2-methoxyphenyl]ethanone 373642-28-5P 373642-30-9P 373642-32-1P, N,N-Dibenzyl-4-iodo-3,5-dimethylaniline 373642-34-3P, (4-Benzyloxy-3-isopropylphenyl)(4-dibenzylamino-2,6-dimethylphenyl)methanol 373642-37-6P 373642-39-8P, [4-Benzyloxy-3-(4-fluorophenoxy)phenyl](4-dibenzylamino-2,6-dimethylphenyl)methanol 373642-41-2P 373642-43-4P 373642-45-6P 373642-47-8P 373642-49-0P 373642-51-4P 373642-53-6P, 5-(2,6-Dimethyl-4-nitrophenoxy)-2-hydroxybenzaldehyde 373642-55-8P 373642-61-6P 373642-62-7P 373642-63-8P 373642-66-1P 373642-67-2P 373642-68-3P 373642-69-4P 373642-70-7P 373642-71-8P 373642-72-9P 373642-73-0P 373642-75-2P 373642-76-3P 373642-77-4P 373642-78-5P 373642-79-6P 373642-80-9P, 3-[3-[5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxybenzyl]phenyl]propanoic acid 373642-82-1P 373642-83-2P, 1-[5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxyphenyl]-2-cyclohexylethanone 373642-84-3P, 4-(4-Amino-2,6-dimethylphenoxy)-2-(2-cyclohexylethyl)phenol 373642-85-4P, 4-(4-Amino-2,6-dimethylphenoxy)-2-isopropyl-3-methoxyphenol 373642-86-5P, 4-[4-Methoxy-3-[2-(2-methoxyphenyl)ethyl]phenoxy]-3,5-dimethylaniline 373642-87-6P, (4-Amino-2,6-dimethylphenyl)(4-hydroxy-3-isopropylphenyl)methanone 373642-88-7P, 4-(4-Amino-2,6-dimethylbenzyl)-2-isopropylphenol 373642-89-8P, 4-(4-Methoxybenzyl)-3,5-dimethylaniline 373642-91-2P, 4-(4-Amino-2,6-dimethylphenoxy)-2-(4-tetrahydropyranyloxy)phenol 373642-92-3P, 4-(4-Amino-2,6-dimethylbenzyl)-2-(4-tetrahydropyranyloxy)phenol 373642-93-4P, 1-(4-Amino-2,6-dimethylphenoxy)-4-benzyloxy-5,6,7,8-tetrahydronaphthalene 373642-94-5P, 4-(4-Benzyloxy-3-isopropylphenoxy)-2,3,5-trichloroaniline 373642-95-6P, 4-(4-Benzyloxy-3-isopropylphenoxy)-3,5-dibromoaniline 373642-96-7P 373642-97-8P, 4-(4-Benzyloxy-5,6,7,8-tetrahydro-1-naphthyloxy)-2,3,5-trichloroaniline 373642-98-9P, 6-[5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxybenzyl]-2H-pyridazin-3-one 373643-00-6P 373643-01-7P 373643-02-8P 373643-03-9P 373643-04-0P 373643-05-1P, 2,2,2-Trifluoro-N-[4-(4-methoxybenzyl)-3,5-dimethylphenyl]acetamide 373643-06-2P, 2,2,2-Trifluoro-N-[4-[3-(4-fluorobenzoyl)-4-hydroxybenzyl)-3,5-dimethylphenyl]acetamide 373643-07-3P 373643-08-4P, 4-(4-Amino-2,6-dimethylphenoxy)-2-(2-cyclohexyl-1-hydroxyethyl)phenol 373643-09-5P, [5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxyphenyl](2-methoxyphenyl)methanone 373643-10-8P, [5-(4-Amino-2,6-dimethylphenoxy)-2-hydroxyphenyl](2-hydroxyphenyl)methanone 373643-11-9P 373643-12-0P, 4-(4-Amino-2,6-dimethylbenzyl)-2-(4-fluorophenoxy)phenol 373643-15-3P 373643-16-4P 373643-17-5P 373643-18-6P 373643-19-7P 373643-20-0P **373643-21-1P** 373643-23-3P 477274-13-8P 477274-14-9P, [2-Benzyloxy-5-(2,6-dimethyl-4-nitrophenyl)phenyl]methanol 477274-15-0P, [5-(2,6-Dimethyl-4-nitrophenyl)-2-methoxyphenyl]methanol 477274-16-1P, 2-(2-Cyclohexylethyl)-4-(2,6-dimethyl-4-nitrophenyl)phenol 477274-17-2P, 4-(4-Amino-2,6-dimethylphenoxy)-2-(4-fluorophenoxy)phenol 477274-18-3P 477274-19-4P, Ethyl 4-(4-benzyloxy-3-isopropylbenzyl)-3,5-dimethylmalonanilate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preventive or recurrence-suppressive agents for liver cancer contg. thyroid hormone receptor agonists)

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:833261 CAPLUS
DN 135:371762

TI Preparation of malonanilic acid derivatives as preventives or remedies for circulatory disease

IN Shiohara, Hiroaki; Nakamura, Tetsuya; Kikuchi, Norihiko; Ohnota, Hideki; Koizumi, Takashi; Kitazawa, Makio

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085670	A1	20011115	WO 2001-JP3499	20010424

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-140743 A 20000512

OS MARPAT 135:371762

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT **355129-15-6P** **355129-23-6P** 364331-19-1P 364331-20-4P
364331-24-8P 364332-53-6P 364332-59-2P 364332-60-5P 373641-11-3P
373641-12-4P 373641-13-5P 373641-14-6P 373641-15-7P 373641-17-9P
373641-18-0P 373641-19-1P 373641-22-6P 373641-24-8P 373641-25-9P
373641-27-1P 373641-29-3P 373641-31-7P 373641-34-0P 373641-38-4P
373641-40-8P 373641-42-0P 373641-44-2P 373641-46-4P
373641-50-0P 373641-51-1P 373641-53-3P 373641-54-4P 373641-55-5P
373641-56-6P 373641-57-7P 373641-58-8P 373641-59-9P
373641-60-2P 373641-61-3P 373641-62-4P 373641-63-5P
373641-64-6P 373641-65-7P 373641-66-8P 373641-67-9P 373641-68-0P
373641-69-1P 373641-70-4P 373641-71-5P 373641-72-6P 373641-73-7P
373641-74-8P 373641-75-9P 373641-76-0P 373641-77-1P 373641-78-2P
373641-79-3P 373641-80-6P 373641-81-7P 373641-82-8P 373641-83-9P
373641-84-0P 373641-85-1P 373641-86-2P 373641-87-3P 373641-88-4P
373641-89-5P 373641-90-8P 373641-91-9P 373641-92-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of malonanilic acid derivs. lowering neutral fat level and non-HDL cholesterol level in blood as preventives or remedies for circulatory diseases)

IT 3886-19-9P 4049-39-2P 20404-02-8P 23860-35-7P, Cyclohexaneacetyl chloride 29417-96-7P 40500-05-8P 53906-85-7P 85064-61-5P
89682-88-2P 92892-06-3P 103260-44-2P 112556-09-9P 117832-15-2P
130312-00-4P 156740-97-5P 224648-57-1P 355377-72-9P 373641-93-1P
373641-94-2P 373641-95-3P 373641-96-4P 373641-97-5P 373641-98-6P
373641-99-7P 373642-00-3P 373642-01-4P 373642-02-5P 373642-03-6P
373642-05-8P 373642-07-0P 373642-09-2P 373642-10-5P 373642-12-7P
373642-14-9P 373642-16-1P 373642-18-3P 373642-20-7P 373642-22-9P
373642-24-1P 373642-26-3P 373642-28-5P 373642-30-9P 373642-32-1P
373642-34-3P 373642-37-6P 373642-39-8P 373642-41-2P 373642-43-4P
373642-45-6P 373642-47-8P 373642-49-0P 373642-51-4P 373642-53-6P
373642-55-8P 373642-57-0P 373642-59-2P 373642-61-6P 373642-62-7P
373642-63-8P 373642-64-9P 373642-65-0P 373642-66-1P 373642-67-2P
373642-68-3P 373642-69-4P 373642-70-7P 373642-71-8P 373642-72-9P
373642-73-0P 373642-74-1P 373642-75-2P 373642-76-3P 373642-77-4P

373642-78-5P 373642-79-6P 373642-80-9P 373642-81-0P 373642-82-1P
373642-83-2P 373642-84-3P 373642-85-4P 373642-86-5P 373642-87-6P
373642-88-7P 373642-89-8P 373642-90-1P 373642-91-2P 373642-92-3P
373642-93-4P 373642-94-5P 373642-95-6P 373642-96-7P 373642-97-8P
373642-98-9P 373642-99-0P 373643-00-6P 373643-01-7P 373643-02-8P
373643-03-9P 373643-04-0P 373643-05-1P 373643-06-2P 373643-07-3P
373643-08-4P 373643-09-5P 373643-10-8P 373643-11-9P 373643-12-0P
373643-13-1P 373643-14-2P 373643-15-3P 373643-16-4P 373643-17-5P
373643-18-6P 373643-19-7P 373643-20-0P **373643-21-1P**
373643-23-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of malonanilic acid derivs. lowering neutral fat level and non-HDL cholesterol level in blood as preventives or remedies for circulatory diseases)

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:730688 CAPLUS
DN 135:288519
TI Preparation of N-phenylmalonamic acid derivatives with thyroid receptor ligand activity
IN Aspnes, Gary Erik; Chiang, Yuan-Ching Phoebe; Estep, Kimberly Gail
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072692	A1	20011004	WO 2001-IB317	20010307
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1268404	A1	20030102	EP 2001-910082	20010307
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009625	A	20030422	BR 2001-9625	20010307
	JP 2003528847	T2	20030930	JP 2001-570607	20010307
	US 2001051657	A1	20011213	US 2001-819283	20010328
	BG 107036	A	20030430	BG 2002-107036	20020826
	NO 2002004639	A	20020927	NO 2002-4639	20020927
PRAI	US 2000-193618P	P	20000331		
	WO 2001-IB317	W	20010307		

OS MARPAT 135:288519
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT 298695-13-3P, N-[4-[3-(4-Fluorobenzenesulfonyl)-4-hydroxyphenoxy]-3,5-dimethylphenyl]malonamic acid **355129-16-7P** 364331-20-4P
364331-21-5P 364331-22-6P 364331-23-7P 364331-24-8P
364331-31-7P 364331-33-9P 364331-35-1P 364331-37-3P 364331-38-4P
364331-39-5P 364331-40-8P 364331-41-9P 364331-42-0P
364331-43-1P 364331-44-2P 364331-45-3P 364331-47-5P 364331-48-6P
364331-49-7P 364331-50-0P **364331-55-5P** 364331-56-6P
364331-57-7P 364331-58-8P **364331-59-9P** **364331-61-3P**
364331-63-5P **364331-65-7P** 364331-67-9P

364331-69-1P 364331-71-5P 364331-73-7P
364331-75-9P 364331-77-1P 364331-79-3P
364331-81-7P 364331-83-9P 364331-85-1P
364331-88-4P 364331-90-8P 364331-92-0P
364331-94-2P 364331-96-4P 364331-97-5P
364331-98-6P 364331-99-7P 364332-00-3P
364332-05-8P 364332-06-9P 364332-08-1P 364332-10-5P 364332-11-6P
364332-12-7P 364332-13-8P 364332-14-9P 364332-20-7P 364332-21-8P
364332-22-9P 364332-23-0P 364332-24-1P 364332-25-2P 364332-26-3P
364332-27-4P 364332-28-5P 364332-29-6P 364332-30-9P 364332-31-0P
364332-32-1P 364332-33-2P 364332-34-3P 364332-35-4P 364332-36-5P
364332-37-6P 364332-38-7P 364332-39-8P 364332-40-1P 364332-41-2P
364332-42-3P 364332-43-4P 364332-44-5P 364332-46-7P 364332-47-8P
364332-48-9P 364332-49-0P 364332-50-3P 364332-51-4P 364332-53-6P
364332-54-7P **364332-55-8P 364332-56-9P**
364332-57-0P 364332-58-1P 364332-60-5P 364332-61-6P
364332-68-3P 364332-70-7P 364332-71-8P 364332-72-9P 364332-73-0P
364332-74-1P 364332-75-2P 364332-76-3P 364332-77-4P 364332-78-5P
364332-79-6P 364332-80-9P 364332-81-0P 364332-82-1P 364332-83-2P
364332-84-3P 364332-86-5P 364332-90-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-phenylmalonamates with thyroid receptor ligand activity)

IT 102914-99-8P, 2-(4-Fluorobenzenesulfonyl)benzene-1,4-diol 156740-86-2P
156740-87-3P 156740-88-4P 156740-96-4P 290349-18-7P,
5-(2,6-Dichloro-4-nitrophenoxy)-2-methoxybenzenesulfonyl chloride
290349-80-3P, 5-(2,6-Dichloro-4-nitrophenoxy)-2-methoxybenzaldehyde
290349-81-4P, 5-(2,6-Dichloro-4-nitrophenoxy)-2-methoxybenzoic acid
290351-96-1P 298695-35-9P, 4-(2,6-Dimethyl-4-nitrophenoxy)-2-(4-fluorobenzenesulfonyl)phenol 298695-37-1P, 4-(4-Amino-2,6-dimethylphenoxy)-2-(4-fluorobenzenesulfonyl)phenol 332933-91-2P
332933-93-4P 364331-18-0P 364331-19-1P 364331-25-9P 364331-26-0P
364331-27-1P 364331-28-2P 364331-51-1P 364331-52-2P 364331-53-3P
364331-54-4P 364332-01-4P 364332-02-5P 364332-03-6P
364332-04-7P 364332-07-0P 364332-09-2P 364332-15-0P 364332-16-1P
364332-18-3P 364332-19-4P 364332-52-5P 364332-59-2P 364332-62-7P
364332-63-8P 364332-64-9P 364332-65-0P 364332-67-2P 364332-69-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-phenylmalonamates with thyroid receptor ligand activity)

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:617969 CAPLUS
DN 135:180607
TI Preparation of aniline-derived ligands for the thyroid receptor
IN Friends, Todd Jason; Ryono, Dennis E.; Zhang, Minsheng
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001060784	A1	20010823	WO 2001-US1204	20010112

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1257526 A1 20021120 EP 2001-903064 20010112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001008134 A 20030930 BR 2001-8134 20010112

NO 2002003895 A 20021016 NO 2002-3895 20020816

PRAI US 2000-183223P P 20000217

WO 2001-US1204 W 20010112

OS MARPAT 135:180607

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT **355129-15-6P 355129-16-7P 355129-17-8P**
355129-18-9P 355129-19-0P 355129-20-3P
355129-21-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aniline-derived ligands for the thyroid receptor)

IT 156740-82-8P 169113-83-1P 258820-25-6P 355129-22-5P
355129-23-6P 355129-24-7P 355129-25-8P **355129-26-9P**
355129-27-0P 355129-28-1P 355129-29-2P **355129-30-5P**
355129-31-6P 355129-32-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aniline-derived ligands for the thyroid receptor)

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:219825 CAPLUS

DN 130:282476

TI Precursors for polybenzoxazoles and polybenzothiazoles

IN Sezi, Recai; Schmid, Gunter; Keitmann, Michael

PA Siemens Aktiengesellschaft, Germany

SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 905169	A2	19990331	EP 1998-117333	19980912
EP 905169	A3	20000112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 11171994	A2	19990629	JP 1998-270388	19980924
US 6153350	A	20001128	US 1998-161148	19980925
PRAI DE 1997-19742132	A	19970924		

IT 222612-31-9P 222612-32-0P 222612-34-2P 222612-35-3P 222612-36-4P
222612-37-5P 222612-38-6P 222612-39-7P 222612-40-0P
222612-41-1P 222612-42-2P 222612-43-3P 222612-45-5P
222612-47-7P 222725-09-9P 222725-10-2P
RL: IMF (Industrial manufacture); PREP (Preparation)
(precursors for polybenzoxazoles and polybenzothiazoles)

IT 222612-31-9DP, cyclized 222612-32-0DP, cyclized 222612-34-2DP, cyclized 222612-35-3DP, cyclized 222612-36-4DP, cyclized 222612-37-5DP, cyclized 222612-38-6DP, cyclized 222612-39-7DP, cyclized 222612-40-0DP, cyclized **222612-41-1DP**, cyclized 222612-42-2DP, cyclized 222612-43-3DP, cyclized 222612-45-5DP, cyclized 222612-47-7DP, cyclized 222725-09-9DP, cyclized 222725-10-2DP, cyclized
RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)

(prepn. of)

=> d bib, hitstr 5-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:617969 CAPLUS
DN 135:180607
TI Preparation of aniline-derived ligands for the thyroid receptor
IN Friends, Todd Jason; Ryono, Dennis E.; Zhang, Minsheng
PA Bristol-Myers Squibb Co., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060784	A1	20010823	WO 2001-US1204	20010112
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1257526	A1	20021120	EP 2001-903064	20010112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008134	A	20030930	BR 2001-8134	20010112
	NO 2002003895	A	20021016	NO 2002-3895	20020816
PRAI	US 2000-183223P	P	20000217		
	WO 2001-US1204	W	20010112		

OS MARPAT 135:180607
IT **355129-15-6P 355129-16-7P 355129-17-8P**
355129-18-9P 355129-19-0P 355129-20-3P
355129-21-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aniline-derived ligands for the thyroid receptor)
RN 355129-15-6 CAPLUS
CN Propanoic acid, 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 355129-16-7 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-

methylethyl)phenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 355129-17-8 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 355129-18-9 CAPLUS
CN Butanoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 355129-19-0 CAPLUS
CN Pentanoic acid, 5-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 355129-20-3 CAPLUS
CN 2-Butenoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 355129-21-4 CAPLUS
CN 2-Butenoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **355129-23-6P 355129-26-9P 355129-30-5P 355129-31-6P 355129-32-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aniline-derived ligands for the thyroid receptor)

RN 355129-23-6 CAPLUS
CN Propanoic acid, 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 355129-26-9 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 355129-30-5 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(1-methylethyl)phenoxy]-2-methylphenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 355129-31-6 CAPLUS
CN Butanoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 355129-32-7 CAPLUS
CN 2-Butenoic acid, 4-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-4-oxo-, methyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:219825 CAPLUS
DN 130:282476
TI Precursors for polybenzoxazoles and polybenzothiazoles
IN Sezi, Recai; Schmid, Gunter; Keitmann, Michael
PA Siemens Aktiengesellschaft, Germany
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 905169	A2	19990331	EP 1998-117333	19980912
	EP 905169	A3	20000112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 11171994	A2	19990629	JP 1998-270388	19980924
	US 6153350	A	20001128	US 1998-161148	19980925
PRAI	DE 1997-19742132	A	19970924		

IT **222612-41-1P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(precursors for polybenzoxazoles and polybenzothiazoles)
RN 222612-41-1 CAPLUS
CN Poly[oxy(2,3,5,6-tetrafluoro-1,4-phenylene)oxy(2,3,6-trifluoro-5-hydroxy-1,4-phenylene)imino(1,6-dioxo-1,6-hexanediyl)imino(2,3,5-trifluoro-6-hydroxy-1,4-phenylene)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

n

IT **222612-41-1DP**, cyclized
RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)
(prepn. of)
RN 222612-41-1 CAPLUS
CN Poly[oxy(2,3,5,6-tetrafluoro-1,4-phenylene)oxy(2,3,6-trifluoro-5-hydroxy-1,4-phenylene)imino(1,6-dioxo-1,6-hexanediyl)imino(2,3,5-trifluoro-6-

hydroxy-1,4-phenylene)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B